Search results
Results from the WOW.Com Content Network
The Drug Rebate Equalization Act of 2009 (DRE), introduced in the 111th United States Congress by Representative Bart Stupak as H.R. 904, and in the Senate by Senator Jeff Bingaman as S. 547, sought to equalize the treatment of prescription drug discounts between Medicaid managed care and Medicaid fee-for-service.
It required pharmaceutical manufacturers to provide rebates for medication purchases, based on sales to Medicaid beneficiaries, as a condition of having their products covered by Medicaid. [3] The amount of the rebates paid to the states were based on a "best price" calculation that did not take into account the discounted prices that ...
The Sunshine Act requires manufacturers of drugs, medical devices, biological and medical supplies covered by the three federal health care programs Medicare, Medicaid, and State Children's Health Insurance Program (SCHIP) to collect and track all financial relationships with physicians and teaching hospitals and to report these data to the Centers for Medicare and Medicaid Services (CMS).
Pandemic-ravaged hospitals that serve poor and low-income New Yorkers will get $3.2 billion in aid under the recently approved state budget for 2025, according to Gov. Kathy Hochul's estimates ...
False Claims Act, Medicaid Rebate Statute 2007 Purdue Pharma [15] $601 million Off-label promotion Oxycontin: False Claims Act 2010 Allergan [16] $600 million Off-label promotion Botox: False Claims Act, FDCA 2010 AstraZeneca [17] $520 million Off-label promotion, kickbacks Seroquel: False Claims Act 2007 Bristol-Myers Squibb [18] $515 million
Yet there are gaps in how the billions of taxpayer-supported funding for Medicaid programs in New York addresses maternal health needs. ... About 17% of women ages 18 to 49 on Medicaid who needed ...
The company expects the number of consumers served to be 50.97 million-51.32 million, including 8.4 million-8.45 on Medicare Advantage and 7.675 million–7.775 million on Medicaid.
The Medicaid drug rebate for brand name drugs, paid by drug manufacturers to the states, is increased to 23.1% (except for the rebate for clotting factors and drugs approved exclusively for pediatric use, which increases to 17.1%), and the rebate is extended to Medicaid managed care plans; the Medicaid rebate for non-innovator, multiple source ...